Introduction
============

The mortality rate of patients with shock remains high \[[@B1]\]. Vasodilatory shock is characterized by low arterial blood pressure due to a significantly decreased systemic vascular resistance. The most frequent causes of this type of shock are sepsis and post-cardiovascular surgery requiring cardiopulmonary bypass. However, massive vasodilatation can result from shock of any origin \[[@B1]\].

Aggressive volume resuscitation is the mainstay of initial shock management, followed by vasoactive infusions when fluids do not restore adequate arterial pressure and tissue perfusion \[[@B2]\]. Currently, catecholamines are the preferred vasopressor but the development of adrenergic hyposensitivity with the loss of pressor responsiveness makes finding other options necessary \[[@B3]\]. Additionally, catecholamines - especially dopamine and epinephrine - have significant adverse effects, such as decreased cardiac output and oxygen delivery, arrhythmia, and organ ischemia, especially at high doses. Catecholamines may even increase mortality rates \[[@B3]\].

Vasopressin is a neurohypophyseal hormone with diverse actions mediated by tissue-specific receptors. Low-dose vasopressin and its analog terlipressin have emerged as promising therapies in vasodilatory shock for several reasons. The rationale for using vasopressin and its analogs is the development of relative vasopressin deficiency in patients with vasodilatory shock and the observation that exogenously administered vasopressin restores vascular tone, increases responsiveness to infused catecholamines and raises blood pressure, thereby reducing the need for catecholamine use \[[@B4]\].

Observational and randomized controlled studies involving the use of vasopressin infusion in patients with vasodilatory shock have produced conflicting results. Our aim was to summarize these studies using a systematic review of the literature and a meta-analysis of randomized controlled trials focused on vasopressin and its analog terlipressin in adult patients with vasodilatory shock. We also evaluated vasopressin and terlipressin in studies of septic shock only.

Materials and methods
=====================

Search methods for identification of studies
--------------------------------------------

Studies were identified using the Medline (1966 to 2011) and CENTRAL (1800 to 2011) databases using a sensitive search strategy combining medical subject headings and keywords (see Additional file [1](#S1){ref-type="supplementary-material"} for details). Abstracts from recent major conferences (American Thoracic Society, European Society of Intensive Care Medicine, and Society of Critical Care Medicine) were searched for additional relevant studies. All of the review articles and cross-referenced studies from the retrieved articles were screened for pertinent information.

Selection of studies
--------------------

This meta-analysis was limited to studies that dealt with the role of vasopressin and/or terlipressin compared with catecholamine infusion in the treatment of vasodilatory shock in adult critically ill patients. Vasodilatory shock was defined as hypotension due to peripheral vasodilatation as result of failure of the vascular smooth muscle to constrict \[[@B2]\]. We included trials that satisfied the following inclusion criteria: randomized controlled trials comparing adult critically ill patients who had vasodilatory shock receiving treatment with vasopressin or terlipressin compared with patients not receiving such treatment; survival, biochemical and hemodynamic data; and patients in the studies receiving vasoactive infusion in the control arm and vasopressin plus vasoactive infusion in the experimental arm. Studies were excluded if survival outcome or biochemical and/or hemodynamic data were not provided, if pediatric patients were analyzed, or if they included patients without vasodilatory shock. When we found duplicate reports of the same study in preliminary abstracts and articles, we analyzed data from the most complete dataset.

Data extraction
---------------

Data were independently extracted from each report by three authors, using a data-recording form developed for this purpose. After extraction, data were reviewed and compared by ASN. Disagreements between the two extractors were solved by consensus among the investigators. Whenever needed, additional information concerning a specific study was obtained by directly questioning the principal investigator.

Definition of endpoints
-----------------------

The primary endpoint was overall survival. The survival time was defined as the time from randomization until death from any cause, or was censored on the date of the last follow-up assessment. Secondary endpoints included: change in hemodynamic variables; change in biochemical variables; decrease of catecholamine requirements; and assessment of adverse events.

Statistical analysis
--------------------

The effects of vasopressin and terlipressin on vasodilatory shock outcomes and the adverse effects of these drugs were examined. We extracted data regarding the study design, patient characteristics, treatment duration, medication, dosage, mean change for hemodynamic and biochemical variables, overall survival, and decreased catecholamine requirement. Changes in hemodynamic and biochemical variables were expressed as a percentage and were defined as the final value (after follow-up) minus the baseline value divided by the baseline value. The decreased catecholamine requirement was defined as any sustained decrease in catecholamine infusion over the study follow-up period. Norepinephrine and dopamine infusions were reported as micrograms per minute, vasopressin infusion was reported as units per minute, and terlipressin infusion was reported as micrograms per hour. The conversion of weight-based variables (μ/kg/minute) to time-based variables (μg/minute or μg/hour) was made by multiplying the value by the mean weight, either provided by the author or estimated as 70 kg. The conversion of bolus administration (mg) to continuous administration (μg/hour) was made by dividing the total daily dose by 24 and multiplying it by a conversion factor (mg to μg). All of the time variables were described as hours, and the other variables are described in the text.

For the survival analysis and for the proportion of patients who experienced adverse events, a pooled estimate of the relative risks (RRs) of the individual studies was computed using a fixed-effect model, according to Mantel and Haenszel, and these results graphically represented using forest plot graphs. For continuous variables, the standardized mean difference, which consists of the difference in means divided by the standard deviation, was used. The homogeneity assumption was checked by a chi-squared test with the degrees of freedom equal to the number of analyzed studies minus one. A sensitivity analysis was performed by recalculating the pooled RR estimates for different study subgroups based on the relevant clinical features. This analysis serves to show whether the overall result would be affected by a change in the meta-analysis selection criteria \[[@B5]\]. An estimate of the potential publication bias was carried out by plotting the single-study RR on a log scale against the respective standard error (funnel plot). For multiple comparisons, we used the Bonferroni correction method. Inter-rater reliability was determined by comparing the number of studies searched by Author 1 versus the number searched by Author 2 in each stage of the search by the kappa coefficient \[[@B5]\].

All variables were tested for normality using the Kolgomorov-Smirnov test. The parametric variables were described as the means and standard deviations, and the nonparametric variables were described as the medians and interquartile ranges. All of the analyses were made using Review Manager version 5.1 (Copenhagen: The Nordic Cochrane Center, The Cochrane Collaboration, 2011) and Statistical Package for the Social Sciences version 16.0 (SPSS Inc., Chicago IL, USA). For all analyses, *P*\< 0.05 was considered significant. For publication bias, *P*\< 0.1 was considered significant.

Results
=======

Literature search
-----------------

The search strategy retrieved 105 unique citations. Of these citations, 84 were excluded after the first screening based on the abstracts or titles, leaving 21 articles for a full-text review (Figure [1](#F1){ref-type="fig"}). In this review, 12 articles were excluded for the following reasons: outcome of interest not described (*n*= 5); study design not appropriate (*n*= 4); pediatric patients (*n*= 2); and evaluated vasopressin in both arms (*n*= 1). Finally, nine articles (998 participants) were included in the meta-analysis \[[@B6]-[@B14]\]. For all of the comparisons of inter-rater reliability in each stage of the search, the kappa coefficient ranged from 0.87 to 0.93.

![**Literature search strategy**. AVP, vasopressin.](cc11469-1){#F1}

Study characteristics
---------------------

The characteristics of the nine selected studies are shown in Table [1](#T1){ref-type="table"}. Six studies evaluated vasopressin as a therapeutic approach, two evaluated terlipressin and one study evaluated both. In seven studies the disease responsible for vasodilatory shock was septic shock exclusively, in one study the shock occurred after post-left ventricular assist device, and in the last study the shock occurred post cardiotomy. The mean dose of the drugs across the studies was 38.72 ± 40.14 μg/minute for norepinephrine, 0.055 ± 0.027 U/minute for vasopressin, and 59.03 ± 47.59 μg/hour for terlipressin. The mean age was 61.91 ± 6.29 in entire group, and the median follow-up time was 24 (4.00 to 48.0) hours. The assessment of the study quality is exposed in Table S1 in Additional file [2](#S2){ref-type="supplementary-material"}.

###### 

Characteristics of the studies included in the systematic review

  Study                                  Arms   *n*   Age (years)    Design   Disease                  Dosage           Prognostic index   Time (hours)    MAP objective (mmHg)
  -------------------------------------- ------ ----- -------------- -------- ------------------------ ---------------- ------------------ --------------- ----------------------
  Albanèse and colleagues \[[@B6]\]      N      10    65             RCT      Septic shock             119 μg/minute    29 (APACHE II)     6               65 ± 10
                                         TP     10    66             OL                                50 μg/hour       28 (APACHE II)     6               
  Dünser and colleagues \[[@B7]\]        N      24    68             RCT      Vasodilatory shock       58.8 μg/minute   49.7 (SAPS II)     48              \>70
                                         N+AV   24    68             OL       (PS in 40%)              0.06 U/minute    51.6 (SAPS II)     48              
  Morelli and colleagues \[[@B8]\]       N      15    64             RCT      Septic shock             15 μg/minute     58 (SAPS II)       48              70 ± 5
                                         N+TP   15    67             OL                                110.5 μg/hour    62 (SAPS II)       48              
                                         N+AV   15    66                                               0.03 U/min       60 (SAPS II)       48              
  Morelli and colleagues \[[@B9]\]       N      20    67             RCT      Septic shock             84 μg/minute     59 (SAPS II)       4               70 ± 5
                                         N+TP   19    66             OL       (N \>0.9 μg/kg/minute)   16.6 μg/hour     60 (SAPS II)       4               
  Russell and colleagues \[[@B10]\]      N      382   62             RCT      Septic shock             15 μg/minute     27.1 (APACHE II)   672             65 ± 10
                                         N+AV   397   59             DB       (N \>5 μg/minute)        0.03 U/minute    27 (APACHE II)     672             
  Argenziano and colleagues \[[@B11]\]   N+P    5     52             RCT      Vasodilatory shock       19.7 μg/minute   \-                 0.25            \>70
                                         N+AV   5     52             DB       Post-LVAD                0.1 U/minute                        0.25            
  Patel and colleagues \[[@B12]\]        N      11    68             RCT      Septic shock             17 μg/minute     24 (APACHE II)     4               Physician decision
                                         N+AV   13    68             DB       (high doses of D)        0.06 U/minute    22 (APACHE II)     4               
  Malay and colleagues \[[@B13]\]        N+P    5     56             RCT      Septic shock             12 μg/minute     26 (APACHE II)     24              \>70
                                         N+AV   5     53             DB       0.04 U/minute                             27 (APACHE II)     24              
  Lauzier and colleagues \[[@B14]\]      N      10    58             RCT OL   Septic shock             28.1 μg/minute   23.5 (APACHE II)   48              \>70
                                         N+AV   13    51                      (\<12 hours of shock)    0.09 U/minute    22\. (APACHE II)   48              
  Total                                  C      482   62.23 ± 5.70   \-       \-                       38.72 ± 40.14    \-                 24 (4 to 48)    
                                         AV     472   59.60 ± 7.68                                     0.05 ± 0.02                         36 (24 to 48)   \-
                                         TP     44    66.33 ± 0.57                                     59.03 ± 47.59                       6 (4 to 48)     

Data presented as mean ± standard deviation or median (interquartile range). AV, arginine vasopressin; C, control; D, drug that the patients were already receiving at baseline; DB, double-blind; LVAD, left ventricular assist device; MAP, mean arterial pressure; N, norepinephrine; OL, open-label; P, placebo; PS, post-cardiotomy shock; RCT, randomized controlled trial; TP, terlipressin.

Vasopressin and terlipressin in vasodilatory shock: hemodynamic and biochemical effects
---------------------------------------------------------------------------------------

Table S2 in Additional file [2](#S2){ref-type="supplementary-material"} shows the changes in the hemodynamic variables of the vasopressin, terlipressin, and control patients in each study and in a combined analysis. Compared with the control group, the vasopressin group showed a significant reduction in heart rate (-12.8 ± 6.14% vs. -1.62 ± 6.86%; *P*= 0.023), and a nonsignificant increases in central venous pressure (+19.0 ± 1.41% vs. +10.66 ± 9.29%; *P*= 0.083), stroke volume index (+14.0 ± 8.54% vs. +1.00 ± 2.94%; *P*= 0.05), and left ventricular stroke work index (+65.00 ± 5.65% vs. 29.0 ± 26.54%; *P*= 0.064). When compared with terlipressin group, the vasopressin group showed a nonsignificant smaller reduction in cardiac index (-4.00 ± 9.25% vs. -16.33 ± 4.04%; *P*= 0.070). Compared with the control group, the terlipressin group showed a significant reduction in heart rate (-17.3 ± 7.09% vs. -1.62 ± 6.86%; *P*= 0.011) and oxygen delivery index (-16.0 ± 2.64% vs. -2.0 ± 6.28%; *P*= 0.036), and a borderline significant reduction in the oxygen consumption index (-11.33 ± 6.02% vs. -1.00 ± 5.65%; *P*= 0.071).

Table S3 in Additional file [2](#S2){ref-type="supplementary-material"} shows the changes in the laboratorial variables of the vasopressin, terlipressin, and control patients in each study and in the combined analysis. There were no differences among the groups according to the variables evaluated. In the analyses of the standardized mean difference, we found a significant difference between the terlipressin and control groups in the cardiac index (-0.44 (-0.87 to -0.02); *P*= 0.04) and oxygen delivery index (-0.79 (-1.23 to -0.36); *P*= 0.0004), and a tendency toward a reduction in the gastric PaCO~2~gap difference (-0.47 (-0.96 to 0.01); *P*= 0.06) (Figures S1 to S5 in Additional file [3](#S3){ref-type="supplementary-material"}).

There was a significant reduction in the norepinephrine requirement among the patients receiving either a terlipressin or a vasopressin infusion. In the analyses of the standardized mean difference, there is a significant difference between the vasopressin and control patients (-1.56 (-1.71 to -1.41); *P*\< 0.0001) and between the terlipressin and control patients (-1.97 (-2.62 to -1.32); *P*\< 0.0001) with respect to the norepinephrine dosages (Figure [2](#F2){ref-type="fig"}).

![**Standardized mean difference for norepinephrine reduction between vasopressin/terlipressin and control**. Vasopressin (AVP) and terlipressin (TP) was associated with a significantly standardized mean difference with control (*P*\< 0.0001 for both comparisons). CI, confidence interval; SD, standard deviation.](cc11469-2){#F2}

Vasopressin and terlipressin in vasodilatory shock: mortality and adverse events
--------------------------------------------------------------------------------

The association of vasopressin with a decreased dose of norepinephrine infusion reduced mortality in adult patients (RR, 0.87 (0.76 to 1.00); *P*= 0.05). The terlipressin infusion did not influence mortality (RR, 0.88 (0.62 to 1.25); *P*= 0.47), and in the combined analysis terlipressin + vasopressin resulted in a decreased mortality (RR, 0.87 (0.77 to 0.99); *P*= 0.04) (Figure [3](#F3){ref-type="fig"}). With respect to adverse events, vasopressin and control patients were analyzed because no study that evaluated the effects of terlipressin described adverse events (see Table S4 in Additional file [2](#S2){ref-type="supplementary-material"}). There was no difference in adverse events between the vasopressin and control groups (RR, 0.98 (0.65 to 1.47); *P*= 0.92) (Figure S6 in Additional file [3](#S3){ref-type="supplementary-material"}). There is no correlation between the magnitude of the reduction of norepinephrine during follow-up and the risk ratio for mortality (*r*= 0.143; *P*= 0.652).

![**Meta-analysis of overall survival for vasopressin, norepinephrine and terlipressin combined analyses**. Meta-analysis of overall survival for vasopressin (AVP) + norepinephrine (NE) or terlipressin (TP) + NE in vasodilatory shock, and for AVP + NE in septic shock. CI, confidence interval; M-H, Mantel and Haenszel.](cc11469-3){#F3}

To explore the study heterogeneity, stratified analyses were performed across a number of key study characteristics and clinical factors. The summary of the analysis is shown in Table [2](#T2){ref-type="table"}, and the complete analysis is shown in Table S5 in Additional file [2](#S2){ref-type="supplementary-material"}. In the survival analysis, we found a reduction in mortality with vasopressin patients with septic shock (*P*= 0.05) (Figure [3](#F3){ref-type="fig"}). The number needed to treat for this condition was 1 to 15. This effect on mortality disappeared after analysis without the study by Russell and colleagues \[[@B10]\]. The reduction in norepinephrine requirement was more significant in the double-blinded studies, in patients with septic shock, and with smaller doses of vasopressin and terlipressin. When we analyzed the data without the study by Russell and colleagues \[[@B10]\], the standardized mean difference found was smaller but still significant (Table S5 in Additional file [2](#S2){ref-type="supplementary-material"}).

###### 

Summary of stratified analyses of pooled relative risks and standardized mean difference

  Stratified analysis            Trials   *n*   Vasopressin              *P*value   Heterogeneity   Terlipressin             *P*value   Heterogeneity
  ------------------------------ -------- ----- ------------------------ ---------- --------------- ------------------------ ---------- ---------------
  **Mortality**                                                                                                                         
  Disease                                                                                                                               
   Septic shock                  4        989   0.87 (0.75 to 1.00)      0.05       0.76            0.88 (0.62 to 1.25)      0.47       0.61
   Nonseptic shock               2        58    0.95 (0.65 to 1.37)      0.77       0.46            \-                       \-         \-
  **Norepinephrine reduction**                                                                                                          
  Design                                                                                                                                
   Double-blind                  3        813   -1.75 (-1.91 to -1.59)   \<0.0001   \<0.0001        \-                       \-         \-
   Open-label                    5        170   -0.45 (-0.85 to -0.06)   0.03       0.70            -1.97 (-2.62 to -1.32)   \<0.0001   \<0.0001
  Disease                                                                                                                               
   Septic shock                  6        925   -1.64 (-1.79 to -1.48)   \<0.0001   \<0.0001        -1.97 (-2.62 to -1.32)   \<0.0001   \<0.0001
   Nonseptic shock               2        48    -0.66 (-1.22 to -0.11)   0.02       0.03            \-                       \-         \-
  Vasopressin dosage                                                                                                                    
   ≤0.05 U/minute                2        809   -1.66 (-1.83 to -1.50)   \<0.0001   0.005           \-                       \-         \-
   \>0.05 U/minute               4        105   -0.77 (-1.22 to -0.32)   0.0008     \<0.0001        \-                       \-         \-
  Terlipressin dosage                                                                                                                   
   ≤40 μg/hour                   1        39    \-                       \-         \-              -4.63 (-5.88 to -3.38)   \<0.0001   \-
   \>40 μg/hour                  1        30    \-                       \-         \-              -0.98 (-1.74 to -0.22)   0.01       \-
  **Cardiac index**                                                                                                                     
  Design                                                                                                                                
   Double-blind                  3        46    0.94 (0.29 to 1.58)      0.004      0.45            \-                       \-         \-
   Open-label                    6        190   0.03 (-0.36 to 0.42)     0.89       0.80            -0.44 (-0.87 to -0.02)   0.04       0.54
  Disease                                                                                                                               
   Septic shock                  7        176   0.44 (-0.00 to 0.88)     0.05       0.10            -0.44 (-0.87 to -0.02)   0.04       0.54
   Nonseptic shock               2        58    0.05 (-0.47 to 0.56)     0.86       0.70            \-                       \-         \-
  Terlipressin dosage                                                                                                                   
   ≤40 μg/hour                   1        39    \-                       \-         \-              -0.29 (-0.92 to 0.35)    0.38       \-
   \>40 μg/hour                  2        50    \-                       \-         \-              -0.57 (-1.14 to -0.00)   0.05       0.37
  Follow-up                                                                                                                             
   ≤24 hours                     5        103   0.94 (0.29 to 1.58)      0.004      0.45            -0.48 (-1.00 to 0.04)    0.07       0.28
   \>24 hours                    4        131   0.03 (-0.36 to 0.42)     0.89       0.80            -0.37 (-1.09 to 0.35)    0.31       \-
  Patients                                                                                                                              
   ≤25                           5        87    0.52 (0.02 to 1.03)      0.04       0.12            -0.91 (-1.84 to 0.02)    0.06       \-
   25 to 50                      4        147   0.08 (-0.36 to 0.53)     0.72       0.65            -0.32 (-0.80 to 0.15)    0.18       0.86
  **Oxygen delivery**                                                                                                                   
  Terlipressin dosage                                                                                                                   
   ≤40 μg/hour                   1        39    \-                       \-         \-              -0.75 (-1.40 to -0.10)   0.02       \-
   \>40 μg/hour                  2        50    \-                       \-         \-              -0.83 (-1.42 to -0.25)   0.005      0.38
  **Oxygen consumption**                                                                                                                
  Terlipressin dosage                                                                                                                   
   ≤40 μg/hour                   1        39    \-                       \-         \-              -0.13 (-0.76 to 0.50)    0.69       \-
   \>40 μg/hour                  2        50    \-                       \-         \-              -0.52 (-1.08 to 0.05)    0.07       0.64
  **Gastric PaCO~2~gap**                                                                                                                
  Vasopressin dosage                                                                                                                    
   ≤0.05 U/minute                1        30    -0.38 (-1.11 to 0.34)    0.30       \-              \-                       \-         \-
   \>0.05 U/minute               3        95    0.43 (0.01 to 0.84)      0.04       0.09            \-                       \-         \-
  Terlipressin dosage                                                                                                                   
   ≤40 μg/hour                   1        39    \-                       \-         \-              -0.15 (-0.78 to 0.48)    0.64       \-
   \>40 μg/hour                  1        30    \-                       \-         \-              -0.94 (-1.70 to -0.18)   0.02       \-

Data presented as relative risks (95% confidence interval) for mortality; and as the standardized mean difference (95% confidence interval for cardiac index, norepinephrine reduction, oxygen delivery, oxygen consumption, and gastric PaCO~2~gap.

When analyzing only the double-blinded studies and the patients with septic shock, vasopressin and terlipressin were associated with an increase in cardiac index compared with norepinephrine alone. However, these findings were more significant in the studies with a shorter follow-up and a smaller number of patients. Higher doses of terlipressin (\>40 μg/hour) were associated with decreases in cardiac index, oxygen delivery index, oxygen consumption index, and gastric PaCO~2~gap difference. Further, higher doses of vasopressin (\>0.05 U/minute) were associated with an increased gastric PaCO~2~gap difference. Finally, bolus infusion of terlipressin was associated with a significant reduction of the oxygen delivery index and a borderline significant reduction of the cardiac index. These findings were not found with the continuous infusion. The Grading of Recommendations Assessment, Development and Evaluation (GRADE) evidence profile for the impact of vasopressin for the treatment of vasodilatory shock from this systematic review and meta-analysis of randomized controlled trials is shown in Table S6 in Additional file [2](#S2){ref-type="supplementary-material"}.

Discussion
==========

This systematic review suggests that the combination of vasopressin with norepinephrine in vasodilatory shock is safe, is associated with a reduction in patient mortality, and facilitates weaning of catecholamines, avoiding the latter\'s potential adverse events. Vasopressin and terlipressin did not decrease the cardiac or oxygen delivery indices. All of these changes are more significant in patients with septic shock. The stratified analysis of vasopressin combined with norepinephrine in patients with septic shock was associated with a borderline significant increase in hospital survival when compared with norepinephrine alone.

Vasodilatory shock pathogenesis is multifactorial. Increased nitric oxide, consequent to the activation of inducible nitric oxide synthase, is a major contributor to vasodilatation, acting both directly and via cyclic guanosine monophosphate to lower intracellular calcium levels, to decrease myosin light chain phosphorylation, and to activate calcium-sensitive (KCa) and adenosine triphosphate-sensitive (K~ATP~) K^+^channels \[[@B1],[@B15]\]. An increasing number of studies have consistently found that patients who have vasodilatory shock and are evaluated in the ICU setting have very low plasma levels of vasopressin \[[@B16]\]. Hence, a relative deficiency of vasopressin may also be crucial to the altered functional status of vascular smooth muscle.

The clinical use of vasopressin has followed observations suggesting that exogenous administration of vasopressin during shock increases systemic blood pressure \[[@B17]\]. Blood pressure restoration does not necessarily improve outcome, however, if the increased blood pressure is accompanied by a worsening of cardiac performance and by decreased cardiac output and oxygen delivery \[[@B18],[@B19]\]. High doses of vasopressin are associated with decreased cardiac output, oxygen delivery and consumption, and with increased gastric PaCO~2~gap difference \[[@B20]\]. High-dose vasopressin is thus not indicated as an alternative to other vasopressors for the treatment of vasodilatory shock.

One important limitation to address is that the effects detected by our paper might be related to the decreasing doses of catecholamines instead of the fixed dose of additional vasopressor (although we did not find a relationship between reduction of norepinephrine and mortality). There is a current trend for decatecholaminization of patients, because catecholamines have deleterious effects on immune function, thrombogenicity and metabolic efficiency, on stimulating bacterial growth, and on causing myocardial injury \[[@B21]\]. In fact, higher mortality was noted in those patients where higher mean blood pressure values were generated using a progressively higher catecholamine dose \[[@B21]\].

We also found that vasopressin significantly reduced the heart rate in patients with vasodilatory shock without changes in cardiac output. This is an important finding because it could prevent the development and/or progression of the myocardial dysfunction associated with septic shock and the tachycardia-induced cardiomyopathy \[[@B22]\]. Recent studies also suggest that diastolic dysfunction is a common finding in patients with septic shock and is a major predictor of mortality in these patients \[[@B23]\]. As we already know, reducing the heart rate in patients with diastolic dysfunction can achieve adequate ventricular filling.

We found differences between the regimen used for administration of terlipressin (bolus versus continuous). Previous studies have suggested that intermittent bolus injection may be associated with significant adverse effects, including excessive microregional and systemic vasoconstriction, as well as decreases in cardiac output and oxygen delivery \[[@B24]\]. Conversely, recent studies provide evidence that continuous infusion of low-dose terlipressin exerts beneficial hemodynamic effects with reduced side effects as compared with traditional bolus injection. In general, continuous low-dose terlipressin was associated with improved parameters of myocardial contractility and renal function as well as less vascular leakage compared with bolus injection \[[@B24]\].

The largest randomized controlled trial of vasopressin infusion in septic shock showed no benefit of vasopressin versus norepinephrine \[[@B10]\]. However, this study has some interesting points to be discussed. First, it was found in the vasopressin-treated patients with less severe shock that the 25.8% relative reduction in 28-day mortality compared with norepinephrine was both striking and significant. This result is consistent with the evidence of a better synergistic effect of low-dose vasopressin in isolated arteries with conditions mimicking less severe septic shock \[[@B25]\]. Secondly, the dose of vasopressin chosen is lower than that generally used. Thirdly, the mortality in the control group is lower than the 60% anticipated in the sample size calculation, which could make the study underpowered to detect a significant difference in the outcome. Finally, the mean norepinephrine dose at randomization was considered too low by some studies \[[@B26]\]. However, in our stratified analysis no relationship between the baseline dose of norepinephrine and outcome was found (data not shown).

Polito and colleagues recently published a meta-analysis of vasopressin in vasodilatory shock with important differences from our study \[[@B27]\]. First, we analyzed only adult patients because pediatric shock has a much lower mortality than adult shock and this may contaminate the overall results. Also, we performed a more robust electronic search of references that resulted in the addiction of one study \[[@B11]\] that was missed by Polito and colleagues. Finally, we evaluated a higher number of variables, conducted an analysis based on the standardized mean difference of reduction in norepinephrine requirement, and performed a more robust sensitivity analysis.

These reported findings should be viewed within the context of the limitations of this study and research in the field. Although our literature search procedures were extensive, other trials may have appeared or may not have been published, and publication bias is therefore possible, which could overestimate the efficacy of these treatments. The assessment of adverse effects was limited to those studies in which adverse events were explicitly reported. The changes in hemodynamic and biochemical variables were calculated, and the standard deviations were probably biased because the correlation within patients is not reported. In addition, another limitation of our meta-analysis is that it is dominated by the largest randomized controlled trial from Russell and colleagues \[[@B10]\]. Finally, assumptions used to calculate the drug dosage may have influenced the results.

Conclusions
===========

The present meta-analysis has demonstrated the benefit of the association of vasopressin and terlipressin in reducing norepinephrine requirements in patients with vasodilatory shock, particularly in patients with septic shock. Our results show that vasopressin treatment is not associated with decreased cardiac output or oxygen delivery and consumption, even in higher doses. However, the pooled analyses showed that higher doses of terlipressin were associated with worsening of these variables. Vasopressin significantly reduces mortality in general patients, and specifically in patients with septic shock.

Key messages
============

• Vasopressin and terlipressin reduce the norepinephrine requirements in patients with vasodilatory shock.

• Vasopressin is not associated with decreased cardiac output or oxygen delivery and consumption.

• Vasopressin significantly reduces mortality in patients with septic shock.
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ICU: intensive care unit; PaCO~2~: partial pressure of carbon dioxide; RR: relative risk.
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###### Additional file 2

**Table S1 presenting the assessment of study qualities**. Table S2 presenting the change in hemodynamic variables ((final - baseline value/baseline value) × 100%). Table S3 presenting the change in biochemical variables ((final - baseline value/baseline value) × 100%). Table S4 presenting adverse events. Table S5 presenting stratified analyses of pooled relative risks and standardized mean difference. Table S6 presenting Grading of Recommendations Assessment, Development and Evaluation (GRADE) evidence profile for impact of vasopressin or terlipressin for vasodilatory shock from systematic review and meta-analysis of randomized controlled trials.
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###### Additional file 3

**Figure S1 showing the standardized mean difference of the cardiac index**. Figure S2 showing the standardized mean difference of the oxygen delivery index (DO~2~i). Figure S3 showing the standardized mean difference of the oxygen consumption index (VO~2~i). Figure S4 showing the standardized mean difference of arterial lactate. Figure S5 showing the standardized mean difference of the gastric PaCO~2~gap (Pr-aCO~2~). Figure S6 showing risk for adverse events.
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